Clinical trial
BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women
NCT00074425 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00074425 |
|---|---|
| Title | BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women |
| Official title | Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) NIH National Institute on Drug Abuse (NIDA) National Institute of Mental Health (NIMH) HIV Prevention Trials… |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | BufferGel, PRO 2000/5 Gel, Placebo gel |
| Enrollment | 3,101 |
| Start date | Jan 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Dec 15, 2003 |
| Last update posted | Nov 8, 2021 |
| Countries | Malawi, South Africa, United States, Zambia, Zimbabwe |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: